Pharmaceuticals

Primary Myelofibrosis Market Outlook: Growth and Forecast Highlights 2030

February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the primary myelofibrosis market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Primary Myelofibrosis Market reach by 2030 starting from 2026 levels?

The market size for primary myelofibrosis has demonstrated substantial growth in recent times. This market is anticipated to expand from $0.84 billion in 2025 to $0.9 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.4%. The increase observed in previous periods can be linked to factors such as limited available treatments, issues with delayed diagnosis and misdiagnosis, a low level of disease awareness, dependence on traditional therapies, and a small patient demographic.

The primary myelofibrosis market size is projected to undergo significant expansion over the next few years. It is expected to reach $1.14 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.2%. The expansion during this forecast period can be ascribed to the development of novel targeted therapies, a rise in clinical trial activities, advancements in genetic and molecular diagnostics, increasing investment in hematology research, and the growing adoption of personalized medicine. Prominent trends expected in this timeframe include heightened awareness and early detection of primary myelofibrosis, the proliferation of targeted therapies and individualized treatment methods, a wider embrace of advanced diagnostic tools, an increase in clinical trials and research endeavors, and a focus on patient support programs and disease management strategies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24669&type=smp

Which Drivers Are Influencing Long-Term Growth In The Primary Myelofibrosis Market?

The anticipated rise in myelofibrosis cases is projected to significantly advance the expansion of the primary myelofibrosis market in the future. Myelofibrosis is defined as a rare bone marrow malignancy that interferes with the normal generation of blood cells, causing substantial scar tissue formation within the bone marrow, which in turn leads to profound anemia, general weakness, exhaustion, and an enlarged spleen. This growing occurrence of myelofibrosis largely stems from an aging demographic, given that the disease predominantly affects individuals exceeding 60 years of age, and increased life expectancy contributes to a greater volume of diagnosed instances. An elevated prevalence of myelofibrosis enhances the management of primary myelofibrosis through stimulating research efforts, improving early detection, broadening available treatment choices, and fostering superior clinical protocols and specialized patient attention. As an illustration, a report released in November 2024 by the National Institute for Health and Care Excellence, an independent executive non-departmental public body based in the UK, indicated that myelofibrosis affects 3.2 per 100,000 people in the UK, with an incidence rate of 0.6 per 100,000. Consequently, the expanding occurrence of myelofibrosis is fueling the expansion of the primary myelofibrosis market.

How Is The Primary Myelofibrosis Market Divided Into Segments?

The primary myelofibrosis market covered in this report is segmented –

1) By Type: Spinocerebellar Primary Myelofibrosiss, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Other Types

2) By Services: Treatment, Diagnosis

3) By Dosage Forms: Solid, Liquids, Other Dosage Forms

4) By Age: Adult, Child, Geriatric

5) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis, Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis, Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations

2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis, Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis, Ocular Telangiectasia-Associated Myelofibrosis

3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes, Periodic Cytopenia With Fibrosis Flare, Cyclical Myelofibrosis In Autoimmune Disorders

4) By Other Types: Familial Primary Myelofibrosis, Idiopathic Myelofibrosis, Therapy-Related Primary Myelofibrosis, Juvenile Primary Myelofibrosis

Which Trends Are Guiding The Evolution Of The Primary Myelofibrosis Market?

Major companies operating in the primary myelofibrosis market are concentrating on developing innovative products, specifically Janus kinase 2 inhibiting tablets, to enhance symptom management and impede disease progression. Janus kinase 2 (JAK2) inhibiting tablets function as oral medications that impede the JAK2 enzyme’s activity, which plays a role in the irregular signaling pathways leading to excessive blood cell production in primary myelofibrosis. These tablets are effective in decreasing spleen volume, easing symptoms of fatigue and bone pain, and decelerating the disease’s advancement. For example, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a pharmaceutical and biotechnology firm based in Korea, introduced Omjjara (momelotinib), a novel therapy for myelofibrosis. South Korea’s Ministry of Food and Drug Safety has approved it for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who also suffer from moderate to severe anemia. Omjjara is an oral drug that inhibits Janus kinases (JAK1 and JAK2) and activin A receptor type 1 (ACVR1), thereby successfully treating symptoms including anemia, an enlarged spleen, and fatigue. Its approval is substantiated by clinical trial findings showing substantial improvements in anemia, spleen size, and overall symptoms when compared to currently available therapies.

Which Major Industry Participants Are Leading The Primary Myelofibrosis Market Growth?

Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/primary-myelofibrosis-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Primary Myelofibrosis Market?

North America was the largest region in the primary myelofibrosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Primary Myelofibrosis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24669&type=smp

Browse Through More Reports Similar to the Global Primary Myelofibrosis Market 2026, By The Business Research Company

Myelodysplastic Syndrome Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report

Myeloproliferative Disorders Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Thrombectomy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/thrombectomy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795